Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression (NCT05373680) | Clinical Trial Compass
CompletedPhase 2/3
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
Egypt118 participantsStarted 2022-01-01
Plain-language summary
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with mild or/and moderate chronic kidney disease (stages 2 or/and 3, estimated glomerular filtration rate (eGFR) between 30-89 ml/min/1.73 m2) at the time of the baseline visit.
* Patients with and without type 2 diabetes.
* Patients with or without proteinuria.
* Age: ≥ 18 years.
Exclusion Criteria:
* Type 1 diabetes.
* Patients with eGFR Ë‚30 ml/min/1.73 m2.
* Patients with known hepatic cell failure.
* Decompensated heart requiring acute management.
* Active malignancy.
* Planned coronary or surgical interventions.
* Known hypersensitivity to study medications.
* Chronic inflammation, trauma, or infection.
* Pregnant or lactating women.
* Patients already on metformin or a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
* Any of the study treatments labeled contraindications.
What they're measuring
1
Change in estimated glomerular filtration rate (eGFR) values from baseline